Hemogenyx Pharmaceuticals (LSE:HEMO) Total Assets : £6.11 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals Total Assets?

Hemogenyx Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was £6.11 Mil.

During the past 12 months, Hemogenyx Pharmaceuticals's average Total Assets Growth Rate was 6.50% per year. During the past 3 years, the average Total Assets Growth Rate was 78.60% per year. During the past 5 years, the average Total Assets Growth Rate was 67.30% per year.

During the past 9 years, Hemogenyx Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 141.90%. The lowest was -3.90%. And the median was 62.35%.

Total Assets is connected with ROA %. Hemogenyx Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -71.12%. Total Assets is also linked to Revenue through Asset Turnover. Hemogenyx Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Hemogenyx Pharmaceuticals Total Assets Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals Total Assets Chart

Hemogenyx Pharmaceuticals Annual Data

Trend

Feb15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

1.05

2.67

8.52

7.09

6.11

Hemogenyx Pharmaceuticals Semi-Annual Data
	Feb15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	Get a 7-Day Free Trial												8.52	7.84	7.09	7.22	6.11

Hemogenyx Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Hemogenyx Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	2.781	+	3.325
	=	6.11

Hemogenyx Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	2.781	+	3.325
	=	6.11

Hemogenyx Pharmaceuticals (LSE:HEMO) Total Assets Explanation

Total Assets is connected with ROA %.

Hemogenyx Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-4.74	/	( (7.224	+	6.106)	/ 2 )
	=	-4.74	/	6.665
	=	-71.12 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Hemogenyx Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (7.224	+	6.106)	/ 2 )
=	0	/	6.665
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Hemogenyx Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals (LSE:HEMO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

5HU:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (LSE:HEMO) Headlines

No Headlines